LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Home・Akciju saraksts・MediciNova Inc

MediciNova Inc

Slēgts

SektorsVeselības aprūpe

1.31

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

1.28

Max

1.32

Galvenie mērījumi
By Trading Economics
Ienākumi	216K -2.6M
Pārdošana	35K 187K
EPS	-0.05
Peļņas marža	-1,383.144
Darbinieki	6
EBITDA	63K -2.8M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+506.06% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 12. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-2M 67M
Iepriekšējā atvēršanas cena	1.31
Iepriekšējā slēgšanas cena	1.31

Ziņu noskaņojums

By Acuity

26%

74%

59 / 344 Rangs Healthcare

MediciNova Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 4. jūn. 21:51 UTC

Galvenie tirgus virzītāji

Merlin Shares Rally After Defense Department's Design Review Wraps

2026. g. 4. jūn. 23:46 UTC

Tirgus saruna

U.S. Jobs Data May Offer Bullish Catalyst for Dollar Vs. Yen -- Market Talk

2026. g. 4. jūn. 23:44 UTC

Tirgus saruna

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

2026. g. 4. jūn. 23:42 UTC

Iegādes, apvienošanās, pārņemšana

Energy Resources of Australia: Court to Decide on Rio Tinto Compulsory Acquisition Request

2026. g. 4. jūn. 23:41 UTC

Iegādes, apvienošanās, pārņemšana

Energy Resources of Australia to Enter Trading Halt

2026. g. 4. jūn. 23:34 UTC

Tirgus saruna

Oil Edges Lower Amid Mixed Middle East Developments -- Market Talk

2026. g. 4. jūn. 23:31 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 4. jūn. 23:31 UTC

Tirgus saruna

Mercury NZ Loses Bull Despite Sector Earnings Powering Up -- Market Talk

2026. g. 4. jūn. 23:31 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 4. jūn. 23:08 UTC

Tirgus saruna

Narrowing Rate Differentials Make Australian Dollar Less Attractive Versus USD -- Market Talk

2026. g. 4. jūn. 22:41 UTC

Tirgus saruna

Australia Shares Set to Rise at the Open -- Market Talk

2026. g. 4. jūn. 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 4. jūn. 20:44 UTC

Iegādes, apvienošanās, pārņemšana

RTX Stock Rises After Catching an Upgrade. Why This Analyst Is Bullish. -- Barrons.com

2026. g. 4. jūn. 20:16 UTC

Tirgus saruna

Mexican Demand Indicators Show Signs of Life -- Market Talk

2026. g. 4. jūn. 20:15 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences And Lakefront Complete Acquisition Of Ouro Medicines To Further Expand Inflammation Pipeline >GILD

2026. g. 4. jūn. 19:46 UTC

Tirgus saruna

Treasury Yields Decline Ahead of U.S. Payrolls -- Market Talk

2026. g. 4. jūn. 19:38 UTC

Tirgus saruna

Oil Futures Retreat After 3-Session Winning Streak -- Market Talk

2026. g. 4. jūn. 19:30 UTC

Tirgus saruna

U.S. Natural Gas Futures Rise on Weather, Storage Data -- Market Talk

2026. g. 4. jūn. 18:47 UTC

Iegādes, apvienošanās, pārņemšana

Google Stock Attracts Cathie Wood's ARK and Berkshire Hathaway. That's Rare. -- Barrons.com

2026. g. 4. jūn. 18:38 UTC

Peļņas

Money Quote: Tech Weakness in Context -- WSJ

2026. g. 4. jūn. 18:24 UTC

Peļņas

Quantinuum, Broadcom, UnitedHealth, and More Stocks That Explain Today's Market -- Barrons.com

2026. g. 4. jūn. 17:09 UTC

Tirgus saruna

Retest of $55k Seen Possible for Bitcoin -- Market Talk

2026. g. 4. jūn. 16:58 UTC

Peļņas

Broadcom, UnitedHealth, Blackstone, Ciena, and More Stocks That Explain Today's Market -- Barrons.com

2026. g. 4. jūn. 16:46 UTC

Tirgus saruna

Strategy BTC Sale Continues to Weigh on Prices -- Market Talk

2026. g. 4. jūn. 16:38 UTC

Peļņas

UnitedHealth Stock Rises. Why the Health Insurer Is Leading the Dow to Sharp Gains. -- Barrons.com

2026. g. 4. jūn. 16:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 4. jūn. 16:20 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2026. g. 4. jūn. 16:13 UTC

Tirgus saruna

On Again, Off Again Deals Keep Oil Market on Edge -- Market Talk

2026. g. 4. jūn. 16:11 UTC

Tirgus saruna

Copper Market Is Awaiting Key U.S. Tariff Decision -- Market Talk

2026. g. 4. jūn. 15:56 UTC

Tirgus saruna

Copper Rises Amid Hormuz Disruptions, U.S. Stockpiling -- Market Talk

Salīdzinājums

Cenas izmaiņa

MediciNova Inc Prognoze

Cenas mērķis

By TipRanks

506.06% augšup

Prognoze 12 mēnešiem

Vidējais 8 USD 506.06%

Augstākais 10 USD

Zemākais 6 USD

Pamatojoties uz 2 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi MediciNova Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

2 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 2 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam MediciNova Inc — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

59 / 344 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par MediciNova Inc

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.